ArticleScientific reports2025
Estimated glucose disposal rate and risk of incident hyperuricemia: insights from CHARLS.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Hyperuricemia (HUA) is a widespread public health problem worldwide, the etiology of HUA is complex, and there is still a lack of accurate indicators to assess HUA when conducting mass epidemiologic screening. Recent studies have shown that insulin resistance (IR) contributes to the development of HUA, and the estimated glucose disposal rate (eGDR) has been recognized as a reliable surrogate for IR. The aim of this study was to investigate the association between eGDR and incident HUA. A total of 9091 participants without HUA at baseline were enrolled in the China Health and Retirement Longitudinal Study. Multivariate logistic regression models were used to analyze the association between eGDR and incident HUA. Restricted cubic spline (RCS) regression modeling was used to examine the dose-response relationship between eGDR and new-onset HUA, and ROC curve analysis was used to test the predictive power of eGDR. Among 9091 participants, 306 new cases of HUA were documented during a median follow-up of 79.4 months. RCS curves showed a significant linear relationship between eGDR and HUA (nonlinear P > 0.05). After full adjustment for covariates (model 3), higher eGDR values were significantly associated with a lower risk of HUA (P < 0.05). The ORs (95% CI) for eGDR Q2-4 were 0.83 (95% CI 0.57-1.19), 0.65 (95% CI 0.45-0.92), and 0.62 (95% CI 0.43-0.89), respectively, for a significantly lower risk of HUA compared with participants with eGDR Q1. When assessed as a continuous variable, each additional standard deviation of eGDR was associated with an 8% reduction in the risk of new-onset HUA (OR 0.92; 95% confidence interval 0.86-0.98; P = 0.006). Higher eGDR was found to be associated with a reduced risk of HUA. This suggests that eGDR may represent one of the promising predictive and intervention targets for HUA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.